These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38633110)

  • 1. Challenges in designing and running smouldering myeloma interventional clinical trials.
    Lecat C; Boyle EM; Hughes D; Lee L; Smith D; Bygrave C; Ramasamy K; Yong K
    EJHaem; 2024 Apr; 5(2):418-420. PubMed ID: 38633110
    [No Abstract]   [Full Text] [Related]  

  • 2. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
    Cowan A; Ferrari F; Freeman SS; Redd R; El-Khoury H; Perry J; Patel V; Kaur P; Barr H; Lee DJ; Lightbody E; Downey K; Argyelan D; Theodorakakou F; Fotiou D; Liacos CI; Kanellias N; Chavda SJ; Ainley L; Sandecká V; Pospíšilová L; Minarik J; Jungova A; Radocha J; Spicka I; Nadeem O; Yong K; Hájek R; Kastritis E; Marinac CR; Dimopoulos MA; Get G; Trippa L; Ghobrial IM
    Lancet Haematol; 2023 Mar; 10(3):e203-e212. PubMed ID: 36858677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
    Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
    Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper.
    Hughes D; Yong K; Ramasamy K; Stern S; Boyle E; Ashcroft J; Basheer F; Rabin N; Pratt G
    Br J Haematol; 2024 Apr; 204(4):1193-1206. PubMed ID: 38393718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study.
    Kyle RA; Larson DR; Therneau TM; Dispenzieri A; Melton LJ; Benson JT; Kumar S; Rajkumar SV
    Lancet Haematol; 2014 Oct; 1(1):e28-e36. PubMed ID: 25530988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice.
    Lonial S; Rajkumar SV; Mateos MV
    Lancet Haematol; 2022 Feb; 9(2):e162-e165. PubMed ID: 35114153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma and physical activity: a scoping review.
    Smith L; McCourt O; Henrich M; Paton B; Yong K; Wardle J; Fisher A
    BMJ Open; 2015 Nov; 5(11):e009576. PubMed ID: 26614625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smouldering multiple myeloma: To seek or not to seek? To treat or not to treat. That is the question.
    Vaxman I; Gatt ME
    Br J Haematol; 2024 Apr; 204(4):1141-1142. PubMed ID: 38429858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.
    Boyle EM; Rosenthal A; Ghamlouch H; Wang Y; Farmer P; Rutherford M; Ashby C; Bauer M; Johnson SK; Wardell CP; Wang Y; Hoering A; Schinke C; Thanendrarajan S; Zangari M; Barlogie B; Dhodapkar MV; Davies FE; Morgan GJ; van Rhee F; Walker BA
    Leukemia; 2022 Feb; 36(2):591-595. PubMed ID: 34365473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic performance of
    Hill E; Mena E; Morrison C; Dew A; Choyke P; Lindenberg L; Kazandjian D
    Br J Haematol; 2021 Apr; 193(1):125-128. PubMed ID: 32966607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case.
    Chiecchio L; Dagrada GP; Protheroe RK; Stockley DM; Smith AG; Orchard KH; Cross NC; Harrison CJ; Ross FM;
    Haematologica; 2009 Jul; 94(7):1024-8. PubMed ID: 19454499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma.
    van de Donk NWCJ; Pawlyn C; Yong KL
    Lancet; 2021 Jan; 397(10272):410-427. PubMed ID: 33516340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum markers alone can define high-risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model.
    Sørrig R
    Br J Haematol; 2020 Jul; 190(2):137-138. PubMed ID: 32220013
    [No Abstract]   [Full Text] [Related]  

  • 14. The difficult business of assessing new therapies for smouldering multiple myeloma.
    Zonder JA
    Br J Haematol; 2018 Aug; 182(4):463-464. PubMed ID: 29767407
    [No Abstract]   [Full Text] [Related]  

  • 15. Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage.
    Wennmann M; Goldschmidt H; Mosebach J; Hielscher T; Bäuerle T; Komljenovic D; McCarthy PL; Merz M; Schlemmer HP; Raab MS; Sauer S; Delorme S; Hillengass J
    Br J Haematol; 2022 Oct; 199(1):65-75. PubMed ID: 35608264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma.
    Dalla Palma B; Marchica V; Pedrazzoni M; Accardi F; Notarfranchi L; Goldoni M; De Luca F; Costa F; Storti P; Toscani D; Sammarelli G; Bonomini S; Aversa F; Giuliani N
    Br J Haematol; 2018 Dec; 183(5):812-815. PubMed ID: 29143308
    [No Abstract]   [Full Text] [Related]  

  • 17. Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials.
    Soomro MA; Hoffman J; Goodman AM; Sborov DW; Mohyuddin GR
    Br J Haematol; 2022 Jun; 197(6):e86-e88. PubMed ID: 35229286
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma.
    Hildebrandt GC; Berno T; Gurule A; Mohan M; Yoon D; Salama M; Zangari M
    Br J Haematol; 2019 Jan; 184(2):308-310. PubMed ID: 29574687
    [No Abstract]   [Full Text] [Related]  

  • 19. Differentiation of benign monoclonal gammopathy and smouldering multiple myeloma from frank myeloma.
    Shimizu K; Ohnishi K; Kunii A
    Clin Exp Immunol; 1982 Dec; 50(3):596-600. PubMed ID: 6819908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival in smouldering myeloma and symptomatic myeloma: Is there an emerging Will Rogers phenomenon?
    Chakraborty R
    Eur J Cancer; 2022 Sep; 172():234-236. PubMed ID: 35797760
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.